Activa Deep Brain Stimulation Therapy System, Percept PC BrainSense
Medtronic, Inc. · Decision date Oct 30, 2026
What did the FDA decide?
The FDA recorded a 30-Day Notice decision coded OK30 on 2026-10-30 for P960009/S548, a supplement to Medtronic, Inc.'s Activa Deep Brain Stimulation Therapy System, Percept PC BrainSense. The device category is an implanted electrical stimulator for parkinsonian tremor, classified under product code MHY in the Neurology specialty. The supplement reason is a process change affecting manufacturer, sterilizer, packager or supplier.
The recorded scope covers three manufacturing changes: adding a new surface mount technology production line, revising the SMT process sequence so automated optical inspection follows each SMT assembly stage, and adding an equivalent solder paste inspection system plus a qualified de-paneling machine for PCBA production. This action concerns production process and equipment only; it is not an approval of the whole system, and no clinical, efficacy or labeling conclusions follow from the record. The source lists no documents, so inspection criteria, validation data and line qualification details remain unknown.
FDA approval order statement
approval for the following three changes: 1) Adding a new surface mount technology (SMT) production line.2) Revision of the SMT manufacturing process sequence to perform automated optical inspection immediately following each SMT assembly stage.3) Addition of an equivalent solder paste inspection system and addition of a qualified de-paneling machine for PCBA production
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Neurology
- Decision date
- Oct 30, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P960009/S548
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- MHY
- Decision code
- OK30
- Decision date
- Oct 30, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, electrical, implanted, for parkinsonian tremor.
- Applicant
- Medtronic, Inc.
- Product code
- MHY
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P960009. Subsequent supplements may change the device or its indications.
FDA decision timeline
P960009 · Original PMA
MEDTRONIC ACTIVA TREMOR CONTROL SYSTEM
P960009/S546 · Related supplement
MEDTRONIC ACTIVA TREMOR CONTROL SYSTEM
P960009/S548 received
Application receipt date recorded by FDA.
P960009/S542 · Related supplement
Activa Deep Brain Stimulation Therapy System, Percept PC BrainSense
P960009/S547 · Related supplement
Activa Deep Brain Stimulation Therapy System, Percept PC BrainSense (DBS Neurostimulator Implantable B35200)
P960009/S548 · FDA decision
30-Day Notice
P960009/S545 · Related supplement
Activa Deep Brain Stimulation Therapy System, Percept PC BrainSense (B32000)
Timeline entries are records held by MedtechLedger for P960009. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P960009
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA approval | Jul 31, 1997 | FDA | |
MEDTRONIC ACTIVA TREMOR CONTROL SYSTEMP960009/S546 | Medtronic, Inc. | PMA supplement | Sep 24, 2026 | FDA |
| Medtronic, Inc. | PMA supplement | Oct 6, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 29, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Nov 8, 2026 | FDA |
Explore the linked device profile
Other records with product code MHY
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
Deep Brain Stimulation (DBS) EPGP140009/S141 | ABBOTT MEDICAL | PMA supplement | Oct 28, 2026 | FDA |
| ABBOTT MEDICAL | PMA supplement | Oct 27, 2026 | FDA | |
Infinity DBS IPGP140009/S139 | ABBOTT MEDICAL | PMA supplement | Sep 23, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 7000 Central Ave., NE, Minneapolis, MN, 55432
Sources and methodology
- Original FDA record: P960009/S548
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
